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Background: The need for lead extraction has been increasing in direct relationship to 
the increased numbers of Cardiovascular Implantable Electronic Devices (CIED).  
Objectives: We sought to examine the safety and efficacy of laser assisted lead extraction and 
the indications, outcomes and risk factors in a large series of consecutive patients.  
METHODS: Consecutive patients undergoing transvenous laser assisted lead extraction at 13 
centers were included.  
RESULTS: Between January 2004 and December 2007, 1449 consecutive patients underwent 
laser assisted lead extraction of 2405 leads (20-270 procedures/site). Median implantation 
duration was 82.1 months (0.4–356.8 mo).  Leads were completely removed 96.5% of the time, 
with a 97.7% clinical success rate where by clinical goals associated with the indication for lead 
removal were achieved. Failure to achieve clinical success was associated with body mass index 
(BMI) <25 and in low extraction volume centers.  Procedural failure was higher in leads 
implanted for >10 years and when performed in low volume centers. Major adverse events 
(MAE) in 20 patients were directly related to the procedure (1.4%) including 4 deaths (0.28%).  
MAE were associated with patients with a BMI <25. Overall all-cause in-hospital mortality was 
1.86%; 4.3% when associated with endocarditis, 7.9% (endocarditis & diabetes), 12.4% 
(endocarditis & creatinine ≥2.0). Indicators of all-cause in-hospital mortality were pocket 
infections, device related endocarditis, diabetes and creatinine ≥ 2.0.   
 CONCLUSIONS: Lead extraction employing laser sheaths is highly successful with a low 
procedural complication rate. Total mortality is substantially increased with pocket infections or 
device related endocarditis, particularly in the setting of diabetes, renal insufficiency or BMI 
<25. Centers with smaller case volumes tended to have a lower rate of successful extraction.  
 Condensed Abstract: 
Between January 2004 and December 2007, 1449 consecutive patients underwent laser assisted 
lead extraction of 2405 leads. 96.5% of leads were completely removed, with a 97.7% clinical 
success rate. Procedural failure was associated with longer implant duration and low volume 
centers. Major adverse events (MAE) related to the procedure occurred in 20 patients including 4 
deaths (0.28%). All-cause in-hospital mortality was 1.86.  
 Laser assisted lead extraction is highly successful with a low procedural complication rate. Total 
mortality is increased with pocket infections or device related endocarditis, Centers with smaller 
case volumes have a lower rate of successful extraction.  
 INTRODUCTION 
The need for percutaneous transvenous lead extraction has been increasingly 
required in direct relationship to the increased numbers of Cardiovascular Implantable 
Electronic Devices (CIED) and is expected to continue to grow.  
Unfortunately the components of the CIED, the leads and pulse generators, do not 
function perpetually. As the population and the CIED ages, components of the system 
need to be extracted for a variety of reasons including infection, lead malfunction, venous 
stenosis and occlusion, as well as safety alerts. Perceptions of lead extraction safety and 
effectiveness and the outcomes of patients undergoing transvenous lead extraction have 
been based on early, relatively small trials, and a voluntary reporting of outcomes in a 
multicenter extraction registry (1-3). Historically the perceived risk of extraction has 
limited the referral and performance of this procedure to patients with life-threatening 
situations (Class 1 indications). Growing physician experience and the development of 
newer tools have impacted the outcomes of transvenous lead extraction and thereby 
indications.  
The goal of this study was to determine the contemporary safety and efficacy of 
excimer laser assisted lead extraction, in a large series of consecutive patients presenting 
to 13 centers. In addition, the indications for extraction, outcomes and risk factors for 
complications and mortality were determined.  
Methods 
Consecutive patients who underwent laser assisted lead extraction (LALE) 
utilizing the CVX-300® (Spectranetics, Colorado Springs, CO) and the SLS II® 
(Spectranetics) laser sheath between January 1, 2004 and December 31, 2007 were 
included.  Patients were excluded if another non-laser, non-traction device was utilized in 
the same procedure.   
 Data was collected at 13 sites in the US and Canada. A pre-study, self-reported 
questionnaire, to determine lead extraction caseloads over the previous four year period, 
and practice type (academic vs. private practice) was utilized to ensure a wide range of 
settings and experience. Centers were divided into 3 groups (small ≤60 cases, mid >60 
and ≤130 and large >130 cases). The protocol was reviewed and approved by the 
institutional review board of each center.   
Definitions published in 2000 in the North American Society of Pacing and 
Electrophysiology (NASPE, now the Heart Rhythm Society, HRS) guidance document 
on transvenous lead extraction were used to calculate the safety and effectiveness of the 
extraction procedure and the rates of procedural (radiographic) and clinical success and 
complications(4). 
Indications for lead extraction were classified as 1) pocket infection, 2) device 
related endocarditis (DRE), 3) pain, 4) venous stenosis or occlusion, 5) functional but 
abandoned or 6) non functional leads.  
Pocket infection was defined as erythema with or without purulent discharge, 
device erosion, fat necrosis, and/or adherence of device to the skin, which may be 
accompanied by pain. All other infections in the presence of a CIED were considered 
device related endocarditis (DRE).  This included all persistent bacteremia or sepsis in 
the absence of another identifiable source or vegetations on the leads or valves in the 
presence of a device. Pain was defined as a lead extraction done to relieve pain associated 
with the device and leads without suspected infection.  Extraction for non functional lead 
status was defined as being related to a mechanical lead failure established on the basis of 
clinically significant alterations in pacing, sensing, lead impedance, or inappropriate 
tachycardia therapies. 
Leads may be extracted when upgrading one system to another such a pacemaker 
to an ICD or a pacemaker/ICD to a cardiac resynchronization device when ispilateral 
venous occlusion or stenosis is encountered. In addition, concern regarding possible 
interference with another device, treatment of malignancy or causing another medical 
condition were indications for extraction.  Potential future venous occlusion and infection 
due to superfluous abandoned leads were also reasons for extraction of the functional 
lead. If venous stenosis or occlusion was present, then the extraction indication was so 
designated, but if the concern was for abandoning leads then the indication was 
designated a “functional abandoned lead.”  
LASER EXTRACTION 
Laser sheaths were employed in all cases when the leads could not be explanted 
by simple traction. The extraction procedure has been described in detail previously(3).   
In brief the lead was prepared by inserting a locking stylet into the inner coil lumen when 
possible. A suture is then tied onto the insulation and the locking stylet. The laser sheath 
was then advanced over the lead. Laser application was performed at binding sites and 
advanced gradually from one binding site to another until the tip of the lead was reached. 
Once abutting the myocardium a combination of traction and countertraction was 
performed and the lead was freed. 
The procedural and clinical success definitions employed in this study were as 
defined in the NASPE 2000 Policy Statement(4).  Procedural success was defined as 
complete or partial, and is identified for each lead extracted.  Complete success was 
defined as the ability to remove “all lead material from the vascular space”. Partial 
success was defined as “removal of all but a small portion of the lead; this may be the 
electrode, 4 cm or less of conductor coil, and/or insulation, or the latter two combined.” 
Procedural failure is defined as “abandoning a significant length of lead (more than 4 cm) 
after attempted removal”.  Clinical success, defined as achievement of “all clinical goals 
associated with the indication for lead removal,” was identified only once for each 
procedure.  At a minimum, the clinical goals included: “resolution of the clinical 
indication for lead removal”; “absence of major complications and control of pacing 
status”.  Clinical failure was defined as the “inability to achieve all of the clinical goals” 
outlined above(4). 
DATA COLLECTION PROCEDURES 
In each institution, a patient identification log was generated which included all 
lead extractions. Each patient was given a unique identifier. Each medical record was 
reviewed from admission to discharge and an initial Data Collection Form (DCF) was 
completed by a trained data collector. To reduce potential bias, a blinded trained second 
data collector then independently reviewed the medical record and completed a second 
DCF on a random selection of ≥10% of the medical records and 100% of the medical 
records of patients who had sustained an adverse event during hospitalization.   
Definitions for major and minor complications (adverse events) are described in 
the NASPE 2000 Policy Statement(4). A major adverse event (MAE) was defined as 
“any complication related to the procedure that required procedural intervention or 
transfusion to prevent death, threat to life, or any complication related to the procedure 
that resulted in death or serious harm to bodily function or structure”. A minor adverse 
event was “any complication related to the procedure that required medical or minor 
procedural intervention to remedy or prolonged hospital stay or limited the patient’s 
function but did not threaten life, cause death or cause serious harm to bodily function or 
structure”. 
The clinical events committee (CEC) reviewed all adverse events. The CEC 
members were blinded to all patient and site identifiers.  The events were reviewed and 
adjudicated as Major or Minor and categorical relationships were defined in relation to 1) 
LALE procedure, 2) another procedure, or 3) pre-existing conditions.  Within the pre-
existing conditions category, specific medical conditions or treatments were further 
evaluated for relationship to the event, including: sepsis, use of anticoagulants, renal 
insufficiency, and loss of biventricular pacing. 
DATA ANALYSIS 
Data analyses were conducted using the SAS system, version 9.1 (SAS Institute 
Inc., Cary, NC, USA).  Descriptive statistics for continuous variables were expressed as 
mean, median, standard deviation and ranges.  Discrete variables were expressed as 
frequencies and percentages. Proportions, such as implant duration category versus 
procedural/clinical success and procedural MAE versus center size, were compared using 
the chi-squared test.   Fisher’s exact test was used for small cell sizes (<5). Median 
implant duration of lead time for MAE versus those leads without MAE was assessed 
utilizing the Wilcoxon Rank Sum Test, due to lack of normality.  All tests of significance 
were two-sided, with statistical significance set at p<0.05.  In addition, surrogate 
modeling was performed for the duration of lead implant in patients who had more than 
one lead extracted.  The longest duration of any lead with LALE was then used to 
represent the individual patient. 
Multivariate logistic regression analysis was performed to determine predictors 
within 6 categories: 1) Clinical failure, 2) Procedural failure, 3) Procedural MAE, 4) All-
cause in-hospital mortality, 5) All-cause in-hospital mortality in the infected population 
(DRE+ pocket infection), and 6) All-cause in-hospital mortality in the DRE population.  
Predictors were selected from the previously conducted univariate analyses where the 
coefficients were significant.  Additional covariate relationships were analyzed, 
interaction/confounding testing was also performed to produce a predictive model at 
p<0.05.  Model-building strategy and goodness of fit test was derived from Hosmer and 
Lemeshow (5).  The candidate variables included in the models included 1) Type of lead 
(pacer or ICD)., 2) Duration of the lead implantation, 3) Volume of procedures at the 
center, 4) Body mass index size <25 (underweight and normoweight), 5) Renal 
insufficiency defined as a pre-procedure serum creatinine ≥2.0 mg/dL 6) Diabetes, 7) 
Endocarditis, 8) Pocket infection, 9) Age > 65 years, and 10) Gender.  
RESULTS 
During the period of January 1, 2004 to December 31, 2007 a total of 1449 
patients underwent LALE in the 13 centers (See Appendix for Centers and cases/ center). 
Physicians had a mean of 11.4 ± 6.32 (range 2.0, 19.0 years, median 13.0) years of 
experience with lead extraction and a mean of 7.87 ± 3.56 (range 2.0, 13.0 years, median 
8.0) years of experience with LALE at the study completion. In these patients extraction 
was attempted on 2405 leads including 1684 pacemaker (70%), 703 defibrillator  
(29.2%), and 18 (0.7%) unknown leads. Most leads were active fixation leads (1226 
Active, 832 Passive, 347 Unknown). Patient characteristics can be seen in Table 1. The 
mean age of patients was 63.4±17.1 years; 71.8% of the patients were male and the mean 
left ventricular ejection fraction (EF) was 37.7%±16.6. Diabetes Mellitus was present in 
403 (27.8%), and 728 (50.2%) had coronary artery disease. Among the 349 patients with 
a reported NYHA class, 41.6% had Class III heart failure symptoms at the time of the 
extraction. Most leads were extracted from the right ventricle (63.5%, n=1528) and right 
atrium (32%, n=769); 11 (0.5%) were located in the SVC, 70 (2.9%) were coronary sinus 
leads and 27 (1.1%) were unknown. The median implant duration was 82.1 months 
(range 0.4–356.8). The number of patients at each site ranged from 20 to 270 patients.  
The indications for lead extraction in the study are presented in Table 2. The most 
common indication for extraction was infection (56.9%, n=825) with 29.2% (n=423) 
related to DRE and 27.7% (n=402) due to pocket infections.  Venous stenosis or 
occlusion was noted in 4.5% (n=65), and pain at the device implant or lead insertion site 
accounted for 0.8% (n=12).  Non-functional leads represented 26.6% (n=386) and 
functional but abandoned leads represented 11.1% (n=161).  Of the functional and non 
functional leads extracted the Medtronic Sprint Fidelis® lead, with or without documented 
failure, contributed 2.5% (n=61) of the patients with 100% clinical and procedural 
success. 
Overall, 2322 leads (96.5%) were completely and 56 leads (2.3%) were partially 
removed with a combined success rate of 98.8%. Clinical success was achieved in 1416 
patients (97.7%). (Table 3)  
The multivariate model indicated that failure to achieve clinical success was 
associated (model likelihood ratio of p=0.0128) with patient body mass index (BMI) < 25  
and when the extraction center volume was ≤ 60 cases over a period of 4 years.  In 
contrast the multivariate model indicated that failure to achieve procedural success was 
associated  (model likelihood ratio of p=0.0005) with lead implantation durations of ≥ 10 
years and when the extraction center volume of extraction was ≤ 60 cases over a period 
of 4 years. 
PROCEDURAL ADVERSE EVENTS 
All-cause adverse events collected during the hospitalization included 63 major 
adverse events in 58 patients (4.0%), and 27 minor adverse events in 26 patients (1.8%). 
Of these, 24 major events in 20 patients (1.4%) and eight minor events in eight patients 
(0.6%) were directly related to the lead extraction portion of the procedure. In addition, a 
total of 27 patients (1.86%) died during the index hospitalization of which four (0.28%) 
were deemed to be directly related to the extraction procedure. Table 4 lists all major and 
minor adverse events noted in the study. The multivariate model indicated that only 
patients with a BMI <25 (p=0.0132) were more likely to experience a procedural MAE 
related to the lead extraction procedure.  Procedural MAE were not significantly 
associated with any other parameter as listed in Table 5.  
IN HOSPITAL MORTALITY AND COMORBIDITIES 
Patients requiring transvenous lead extraction have overlapping comorbidities 
which increase the risk for death during their hospitalization.  The multivariate model 
indicates that patients with creatinine ≥ 2.0, diabetes mellitus, BMI <25 and with 
infection (pocket infection or DRE) were all at increased risk of death (model likelihood 
ratio of p<0.0001). 
Although mortality was higher in patients with DRE compared to pocket 
infection, this difference was not statistically significant 4.35% vs. 1.7% (p=0.06). The 
overall demographic comparisons of patients with infection versus those without 
infection are listed in Table 6. 
There were 825 (56.9%) patients with device related infections, 423 with DRE 
and 402 with pocket infections. The infected patients were more likely to be male, older 
and had slightly better ejection fractions.  In addition, they were more likely to be 
diabetic (35.0% vs. 18.3%, p<0.0001) and have renal insufficiency with a creatinine ≥ 2.0 
mg/dl (16.0% vs. 6.4%, p<0.0001).  The all-cause in-hospital mortality in infected 
patients was also increased (3% vs. 0.3%, p<0.0001, OR=9.7), but there was no 
association with clinical success rate or procedure related MAE rates.  Table 6 
Separately, the DRE patient cohort in-hospital mortality was much higher (4.3%, 18/423) 
compared to the pocket infection patient cohort (1.7%, 7/402).  When diabetes or renal 
insufficiency was additionally present, the DRE patients fared more poorly.  Among 
those DRE patients with concomitant diabetes, 7.9% (13/164) died versus 2% (5/253) 
without a history of diabetes (p=0.0075, OR 4.3). The odds of an in-hospital mortality 
were 7.0 times higher in DRE patients with renal insufficiency (creatinine ≥2.0) than 
among those with DRE and creatinine <2.0 (12.4% vs. 2.0%, p<0.0001).  
 DISCUSSION 
We evaluated the safety and efficacy of laser assisted lead extractions using 
current indications based on the NASPE 2000 Policy Statement. Since the initially 
reported experiences which employed earlier editions of the extraction tools and largely 
represented the learning curve with laser extraction techniques, this consecutive patient 
experience represents the mature contemporary practice in multiple centers with varying 
degrees of experience.  Each of the earlier studies addressed the efficacy and safety of the 
initial models of laser sheath. In this study, the modified SLS II sheath was employed, 
which has improved mechanical properties enhancing advancement over the lead. 
Compared to previous studies, LALE was associated with higher procedural and clinical 
success and a similar procedural related major complication rate, but a lower procedural 
mortality rate. BMI<25 predicted procedural MAE and clinical failure, while renal 
insufficiency, diabetes, BMI <25 and presence of pocket infection or DRE were all 
independent predictors of all cause in-hospital mortality.   The somewhat higher all-cause 
in-hospital mortality of 1.86% reflects the complex co-morbid conditions of this patient 
population, especially DRE.  
The original PLEXES trial, a randomized prospective clinical trial, compared the 
first iteration of the 12-French SLS laser sheath to a non-laser cohort in 301 subjects with 
465 chronic pacemaker leads(3). The procedural success in the laser group was 94% with 
an associated major complication rate of 1.96% compared to 64% success rate with the 
use of only locking stylets and nonpowered telescoping sheaths  . The use of laser tools 
resulted in quicker lead extraction; 10.1 ± 11.5 min vs. with 12.9 ±19.2 min without laser  
(p , 0.04) (3). Subsequently, when the total initial experience of laser lead extraction in 
the United States was reported by Byrd et al on 2,561 pacing and defibrillator leads from 
1,684 patients at 89 sites, the procedural success rate was 90% with a major complication 
rate of 1.9% with an in-hospital death rate of 0.8% (6). Only implant duration 
independently predicted procedure failure and female gender was the only multivariate 
predictor of complications(5). In agreement with the study by Byrd et al, we found that 
longer implantation duration was associated with procedural failure.  In contrast with 
Byrd et al, we found no association between gender and adverse events directly related to 
lead extraction; instead BMI <25 (underweight and normal weight) also predicted 
procedure related MAE.  Additionally, in our study clinical or procedural failure was 
associated with low procedure volumes.   
 
Device related infections continue to be the most common indication for 
extraction (2,3,6,7). Local infection at the pocket site has a variety of presentations 
including erosion, erythema, frank purulent discharge or wound dehiscence, which may 
be accompanied by pain. It is important to recognize and treat these local manifestations 
of infection promptly and effectively so as to prevent festering indolent infections which 
may lead to bacteremia and possible resultant endocarditis as these latter more serious 
sequela are associated with a higher mortality rate(6).  In our study, although the in 
hospital mortality consequence of DRE was numerically larger, the less impressive 
manifestations of pocket infection were statistically not distinguishable from the DRE 
patients.  While there is clear indication that the entire device system should be removed 
in the presence of systemic infection, there has continued to be some controversy 
regarding localized pocket infection. The NASPE 2000 guidelines stated that it was 
acceptable to remove the device and cut the exposed parts of the leads. Such a strategy is 
proving to be unsuccessful and puts the patient at risk of smoldering infection which 
could spread and increase the patient’s risk of death (8). 
In this study, non-pocket infections, which presented as bacteremia, lead or 
valvular vegetations, and/or sepsis were defined as device related endocarditis. We 
elected to classify this group of patients as having DRE because when there is persistent 
bacteremia it is assumed that any intravascular device is seeded and therefore infected. 
About half of all infections were classified as DRE, and these patients were older and had 
a higher rate of diabetes and renal insufficiency (defined as a creatinine ≥2.0). Despite the 
fact that the clinical success and MAE rates were similar to patients with no DRE, the 
risk ratio for all-cause in-hospital mortality in this group of patients was 4.8 times higher 
(4.3%). Patients with DRE and concomitant diabetes had a four times higher mortality 
risk (7.9%) and DRE plus renal insufficiency yielded a 6.3 times higher mortality risk 
(12.4%). This is all compared to the mortality rate in patients without DRE (patients with 
either pocket infections or not infected) of 0.9%.  
The literature reports DRE represents 10-23% of all device infections (8-10).  
DRE represented 51% of device infections in this analysis and is likely due to the broader 
definition employed in our study and the referral patterns of some study centers. This 
broader definition was chosen as the clinical implications of endocarditis, bacteremia and 
sepsis in the setting of a CIED are the same: each requires complete extraction of the 
CIED and prolonged antibiotic therapy.  
Mortality rates of DRE treated medically with antibiotics alone are very high, as 
much as 66% in some series; this is compared to a strategy that employs device 
extraction where mortality in the literature is reported to be 13-21% (11-14). In our study 
the all-cause in-hospital mortality rate for the DRE population was 4.3%, 1.7% for pocket 
infection and 0.3% for all non infected patients.  This emphasizes the seriousness of 
bacteremia and/or vegetations in patients with a CIED system, but also the seriousness of 
pocket infections. In such patients it is imperative to extract and remove the pulse 
generator, the active and abandoned leads and debridement of the infected pocket tissue. 
In agreement with previous studies the presence of  nonfunctional and abandoned 
leads was the second most common indication for extraction(2,3,15). Extraction of leads 
in non-infected patients is considered controversial by some physicians, since there are 
alternative approaches. Non functional leads may be abandoned rather than extracted.  As 
the duration of implant for devices and leads increases along with an aging population, a 
large number of leads become nonfunctional. These can either be extracted at the time of 
another planned procedure such as an upgrade, or be left to be extracted when there is no 
other choice, such as in the presence of infection.This may result in a large number of 
leads in any one patient which over time may pose an increased risk of complications. 
Abandoned leads may also serve as a nidus for lead related endocarditis. In patients with 
device implants of more than 6 months, endocarditis usually resulted from bacteremia 
from a remote source(16).. Suga et al. reported that up to half of all abandoned 
pacemaker leads (611/1207) in their cohort became nonfunctional.  They found that more 
abandoned leads were associated with a greater number of complications(17).  Silvetti et 
al. reported on abandoned leads in young patients. Five and 10 years after lead 
abandonment, 2 patients developed lead endocarditis of a total of 18 patients with 
abandoned leads. The authors concluded that abandonment just postpones inevitable lead 
extraction(18). In this study we found that the success rate was high and the complication 
rate exceeding low for the removal of non-functioning leads. Extraction after some years 
of abandonment may be more difficult and be associated with increased risk. In this study 
there was a progressive increase in procedural failure with prolonged implantation 
duration.  The cumulative rate was 0.75% at 5 years, 0.93% at 10 years, 1.2% at 15 years, 
2.4% at 20 years and 10.9% at 25 years. Procedural failure was statistically increased 
when leads were implanted for >10 years. Extraction of leads may also be needed to 
establish and retain venous access if the target vein is occluded in a situation when there 
is a need for upgrade from a pacemaker(19). In this study, extraction for this indication 
was also associated with a high success rate and low complication rate. When considering 
extraction for a non infection related indication it is very important to weigh the risks for 
a particular patient, including operator experience, against the risk of abandoning these 
leads.  The decision to extract should be individualized and discussed in detail with the 
patient and family. 
It is at this point where the consideration of center laser lead extraction experience 
is most important. Operator experience with laser lead extraction is important in 
determining clinical outcome.  In this study, the small centers had a higher cumulative 
procedural MAE. A less experienced center (≤ 60 cases) was also associated with 
procedural and clinical failure. These findings are in agreement with prior studies 
demonstrating a significant learning curve for this procedure (20).  Therefore, centers 
should consider their extraction volume when deciding to perform this procedure and 
whether extractions should be referred to higher volume centers. 
LIMITATIONS 
The major limitation of this study is its retrospective nature. Although this study 
is a consecutive series, patients who did not undergo laser assisted extraction were not 
included. Therefore there could have been selection bias, but the bias was most likely to 
the most challenging clinical scenarios as laser assisted extraction is reserved for leads 
with ingrown tissue and inability to be removed with traction only. It is possible that the 
high success rate and low complication rates in this study are due to the very experienced 
centers and operators in this study. However, in the community these more challenging 
cases are usually referred to centers experienced in LALE  
Despite this limitation, the study is still valuable because it represents the current 
"real world" experience with LALE. Follow-up was limited in this study to hospital 
discharge or death. The study found a significant mortality in patients with DRE. A 
longer follow-up period would have been valuable in determining the ultimate outcomes 
in this patient population. 
We only studied patients undergoing laser lead extraction. Other techniques are 
currently used. When compared to only countertraction sheaths, powered tools are much 
more effective as the results of the PLEXES trial revealed when this was compared to 
Laser powered sheaths. Electrosurgical dissection sheaths that use radiofrequency are 
also currently in use and achieve a much higher complete extraction rate than non 
powered countertarction sheaths 93% vs 73%. The electrosurgical powered sheaths also 
resulted in less time needed for complete extraction 9.6±6.2min vs. 21±9 min (20).  
A new Evolution Mechanical Dilator Sheath (Cook Medical) with a stainless steel 
bladed rotating tip has been recently introduced and described (21). However the efficacy 
and safety has not been studied in a large patient population and has not been compared 
to standard tools.  There have been no studies comparing the different powered tools to 
each other. 
CONCLUSION 
Transvenous laser assisted lead extraction, is highly successful with a low 
procedural complication rate for a wide range of indications. Device related infection was 
the most common indication for lead extraction and both device related endocarditis and 
pocket infections carry a substantial in-hospital mortality risk despite successful removal 
of the infected device and leads. Therefore an increased emphasis must be placed on 
techniques that reduce the potential for device related endocarditis. Indicators of a 
decreased clinical and procedural success include average to small body mass index, lead 
implantation duration of over 10 years and extraction centers with small extraction 
volumes.  The single indicator of lead extraction associated complications is an average 
or small body mass index, while in hospital mortality is increased by a clinical history of 
pocket infection or device related endocarditis as well as diabetes and renal insufficiency. 
 Table 1: Demographics & Risk Factors 




71.8% Males (n=1041) 
EF 37.7±16.57 % 
DM a 403 (28.1%)  
CAD b 728 (50.1%) 
ICD 703 (29.2%)  
NYHA Class III c 145 (41.6%) 
a: 1433 patients had data regarding history of DM available 
b: 1435 patients had data regarding history of CAD available 
c: 349 patients had data regarding NYHA Class available 
 
Table 2: Indications for Lead Extraction 
1449 Patients Results 
Infection 825 (56.9%) 
       DRE: Sepsis/Endocarditis/Bacteremia 423 (29.2%) 
       Pocket Infection/Erosion – No Bacteremia 402 (27.7%) 
Functional, Abandoned Leads  386 (26.6%) 
Nonfunctional Leads  161 (11.1%) 
Venous Stenosis/Occlusion  65 (4.5%) 






Table 3: Procedural & Clinical Success 
 
      Procedural Success (per Lead) n (%) 
        Complete 2322 (96.5%) 
        Partial 56 (2.3%) 
        Combined Complete and Partial 2378 (98.8%) 
        Failure 27 (1.1%) 
Total 2405 
         Clinical Success (per Patient)              n (%) 
        Success 1416 (97.7%) 





Table 4: Adverse Events  
 
All Cause Adverse Events                    n (%) 
Death 27 (1.86%) 
Bleeding Requiring Transfusion 17 (1.17%) 
Hematoma  requiring drainage 13 (0.90%) 
Cardiac avulsion or tear requiring thoracotomy, 
pericardiocentesis, chest tube, or surgical repair 9 (0.62%) 
Vascular tear requiring thoracotomy, pericardiocentesis, chest 
tube, or surgical repair axillary artery tear requiring surgical 
repair 6 (0.41%) 
Thrombosis of implant vein resulting in medical intervention 4 (0.28%) 
Arrhythmia requiring cardioversion 3 (0.21%) 
Hemothorax from any source requiring transfusion 2 (0.14%) 
Pulmonary embolism not requiring surgical intervention 2 (0.14%) 
Respiratory failure without arrest 2 (0.14%) 
Pulmonary embolism requiring surgical intervention 1 (0.07%) 
Stroke 1 (0.07%) 
Vascular repair near the implant site or venous entry site 1 (0.07%) 
Pericardial effusion not requiring pericardiocentesis or surgical 
intervention 1 (0.07%) 
DVT lower extremity, post op 1 (0.07%) 
Total Events 90 
Minor Adverse Events Directly Related to Lead Extraction n (%) 
Thrombosis of implant vein resulting in medical intervention 3 (0.21%) 
Arrhythmia requiring cardioversion 2 (0.14%) 
Pulmonary embolism not requiring surgical intervention 1 (0.07%) 
Respiratory failure without arrest 1 (0.07%) 
Vascular repair near the implant site or venous entry site 1 (0.07%) 
Total Events (Among 8 Patients) 8 
Major Adverse Events Directly Related to Lead Extraction n (%) 
Cardiac avulsion or tear requiring thoracotomy, 
pericardiocentesis, chest tube, or surgical repair 9 (0.62%) 
Vascular tear (including axillary artery tear) requiring 
thoracotomy, pericardiocentesis, chest tube, or surgical repair 6 (0.41%) 
Bleeding Requiring Transfusion                                 4 (0.28%) 
Death secondary to another major complication 
{3 Vascular tears (2 SVC, 1 SVC/RA), 1 Cardiac Tear (RV)} 4 (0.28%) 
Hemothorax from any source requiring transfusion               1 (0.07%) 
Total Events (Among 20 Patients) 24 
 
Table 5:  Demographic Characteristics: Procedural MAE 
MAE n=20 n (%) p-value 
Center Size (LALE experience over 4 yr study period) 
        ≤60 cases  6 (2.88%) 
        >60 -≤130 cases 8 (1.70%) 
        >130 cases 6 (0.78%) 
0.0532 
Location  
        EP Lab 12 (1.43%) 
        OR 8 (1.36%) 1.00 
Anesthesia 
        General  9 (1.16%) 
        IV Sedation 9 (1.58%) 
        Unknown 2 (1.89%) 
0.68 
Pre Op Arterial Line 
        Present 17 (1.48%) 
        Absent 0 (%) 
        Unknown 3 (1.07%) 
--- 
Gender   
        Male 13 (1.25%) 
        Female 7 (1.72%) 0.66 
BMI   
        < 25 11 (2.6%) 
        ≥25 5 (0.7%) 0.0164 
Diabetes   
        Yes 4 (1.00%) 
         No 16 (1.55%) 0.62 
Renal Insufficiency    
        Cr ≥2.0 5 (3.11%) 
        Cr <2.0 13 (1.10%) 
0.05 
Duration of Lead (Surrogate: longest lead represents each patient) 
        0-5 years 4 (0.80%) 
        >5 to ≤10 years 7 (1.67%) 
        > 10 years 6 (1.8%) 
0.34 
 
Age Mean (± SD)  





TABLE 6:  Device Related Endocarditis and Pocket Infection 
 DRE  
+  
Pocket 
Infection a   
N (%) 
Others  
n  (%) 
p-value 
N 825 (56.9%) 624 (43.1%) <0.0001 
Male (n=1449) 618 (74.9%) 423 (67.8%) 0.003 
Age (n=1449) 67.8 (±14.6)  57.6 (±18.3) <0.0001 
Ejection fraction < 30% (n=1449) 449 (54.4%) 397 (63.6%) 0.0005 
History of Diabetes (n=1449) 289 (35.0%) 114 (18.3%) <0.0001 
History of Renal Failure (CR ≥ 2.0) 
(n=1347) 
125 (16.0%) 36 (6.4%) <0.0001 
History of Renal Failure (CR ≥ 2.5) 
(n=1347) 
93 (11.9%) 19 (3.4%) <0.0001 
Clinical Success (n=1449) 810 (98.2%) 606 (97.1%) 0.24 
Procedure related MAE (n=1449) 12 (1.5%) 8 (1.3%) 0.96 
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